Top

Published in:

22-11-2023 | Seminoma | Original Paper

Overexpression of SerpinB9 in non-seminomatous germ cell tumors

Authors: Toshiki Anami, Yuki Ibe, Lianbo Li, Yoshihiro Komohara, Hiroki Hirao, Mamoru Harada, Hiromu Yano, Yukio Fujiwara, Takanobu Motoshima, Junji Yatsuda, Taizo Hibi, Tomomi Kamba

Published in: Medical Molecular Morphology | Issue 1/2024

Abstract

Serpinb9 is an inhibitor of granzyme B and is potentially involved in the immune escape of tumor cells. In the present study, bioinformatics analysis using open databases suggested that SerpinB9 is overexpressed in testicular embryonal carcinoma. Immunohistological analysis was performed on 28 cases of testicular germ cell tumors to investigate the relationship between SerpinB9 expression in testicular germ cell tumors and the tumor immune environment. SerpinB9 was significantly upregulated in the non-seminoma group and inversely correlated with the number of tumor-infiltrating CD8-positive cells. In addition, yolk sac tumors were characterized by the loss of human leukocyte antigen-class I expression. These findings suggest that SerpinB9 contributes to the immune escape of testicular germ cell tumors. Targeting therapy for SerpinB9 might therefore be useful in immunotherapy for testicular germ cell tumors resistant to immune checkpoint inhibitors.

Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, Fietkau R, Gakis G, Hernández V, Espinós EL, Neuzillet Y, Ribal MJ, Rouanne M, Thalmann GN, van der Heijden AG, Veskimäe E, Alfred Witjes J, Milowsky MI (2022) The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol 81:95–103CrossRefPubMed

Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB (2019) The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer 7:354CrossRefPubMedPubMedCentral

Klein B, Klein T, Konichezky M, Nyska A, Livini E, Levine I, Zamir R, Kooperman O, Lurie H (1990) The expression of HLA class I antigens in germ cell testicular cancer. Am J Clin Pathol 93:202–207CrossRefPubMed

Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 98:11515–11520ADSCrossRefPubMedPubMedCentral

Ibáñez-Molero S, van Vliet A, Pozniak J, Hummelink K, Terry AM, Monkhorst K, Sanders J, Hofland I, Landeloos E, Van Herck Y, Bechter O, Kuilman T, Zhong W, Marine JC, Wessels L, Peeper DS (2022) SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response. Oncoimmunology 11:2139074CrossRefPubMedPubMedCentral

Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, Ichimura T, Banouni N, Dai L, Li X, Greiner DL, Shultz LD, Zhang X, Sun ZJ, Curtin I, Vangos NE, Yeoh ZC, Geffken EA, Seo HS, Liu ZX, Heffron GJ, Shah K, Dhe-Paganon S, Abdi R (2020) Direct tumor killing and immunotherapy through anti-SerpinB9 therapy. Cell 183:1219–1233CrossRefPubMedPubMedCentral

Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21:1505–1512CrossRefPubMed

Dong P, Liu ZW, Li XD, Li YH, Yao K, Wu S, Qin ZK, Han H, Zhou FJ (2013) Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Med Oncol 30:494CrossRefPubMed

Hegde PS, Karanikas V, Evers S (2016) The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin Cancer Res 22:1865–1874CrossRefPubMed

10.

Zemek RM, Chin WL, Nowak AK, Millward MJ, Lake RA, Lesterhuis WJ (2020) Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. Front Immunol 11:223CrossRefPubMedPubMedCentral

11.

Yakirevich E, Lefel O, Sova Y, Stein A, Cohen O, Izhak OB, Resnick MB (2002) Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma. J Pathol 196:67–75CrossRefPubMed

12.

Nouri AM, Hussain RF, Oliver RT, Handy AM, Bartkova I, Bodmer JG (1993) Immunological paradox in testicular tumours: the presence of a large number of activated T-cells despite the complete absence of MHC antigens. Eur J Cancer 29A:1895–1899CrossRefPubMed

13.

Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105:1–8CrossRefPubMed

14.

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399–416CrossRefPubMedPubMedCentral

15.

Komohara Y, Takemura K, Lei XF, Sakashita N, Harada M, Suzuki H, Kodama T, Takeya M (2009) Delayed growth of EL4 lymphoma in SR-A-deficient mice is due to upregulation of nitric oxide and interferon-gamma production by tumor-associated macrophages. Cancer Sci 100:2160–2166CrossRefPubMed

16.

Miyasato Y, Shiota T, Ohnishi K, Pan C, Yano H, Horlad H, Yamamoto Y, Yamamoto-Ibusuki M, Iwase H, Takeya M, Komohara Y (2017) High density of CD204-positive macrophages predicts worse clinical prognosis in patients with breast cancer. Cancer Sci 108:1693–1700CrossRefPubMedPubMedCentral

17.

Hirayama S, Ishii G, Nagai K, Ono S, Kojima M, Yamauchi C, Aokage K, Hishida T, Yoshida J, Suzuki K, Ochiai A (2012) Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol 7:1790–1797CrossRefPubMed

18.

Komohara Y, Kurotaki D, Tsukamoto H, Miyasato Y, Yano H, Pan C, Yamamoto Y, Fujiwara Y (2023) Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes. Cancer Sci 114:2220–2229CrossRefPubMedPubMedCentral

19.

Fendl B, Berghoff AS, Preusser M, Maier B (2023) Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy. ESMO Open 8:100776CrossRefPubMedPubMedCentral

Title: Overexpression of SerpinB9 in non-seminomatous germ cell tumors
Authors: Toshiki Anami
Yuki Ibe
Lianbo Li
Yoshihiro Komohara
Hiroki Hirao
Mamoru Harada
Hiromu Yano
Yukio Fujiwara
Takanobu Motoshima
Junji Yatsuda
Taizo Hibi
Tomomi Kamba
Publication date: 22-11-2023
Publisher: Springer Nature Singapore
Keywords: Seminoma
Seminoma
Nonseminoma
Nonseminoma
Checkpoint Inhibitors
Published in: Medical Molecular Morphology / Issue 1/2024
Print ISSN: 1860-1480
Electronic ISSN: 1860-1499
DOI: https://doi.org/10.1007/s00795-023-00374-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Overexpression of SerpinB9 in non-seminomatous germ cell tumors

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer

Δ3-tubulin impairs mitotic spindle morphology and increases nuclear size in pancreatic cancer cells

Comment to a patient with SLC40A1-HC successfully treated using red blood cell apheresis

Subcellular expression pattern and clinical significance of CBX2 and CBX7 in breast cancer subtypes

Morphological and etiological analyses of C3 and non-C3 glomerulonephritis in primary membranoproliferative glomerulonephritis using periodic acid-methenamine silver stain electron microscopy: a retrospective multicentered study

Pregnancy-specific beta-1-glycoprotein 6 is a potential novel diagnostic biomarker of placenta accreta spectrum